UBS Adjusts CHINARES PHARMA Target Price to HK$6.9, Citing In-Line Revenue and Above-Expectation Net Profit

Stock News03-26

UBS has released a research report adjusting its forecasts for CHINARES PHARMA (03320). The firm raised its earnings per share projections for the company by 14% to 15% from this year through 2028, reflecting reduced tax expenses and lower minority interests. However, it also increased capital expenditure estimates to account for the company's business expansion strategy. The target price for CHINARES PHARMA was lowered from HK$7.5 to HK$6.9, while the "Buy" rating was maintained. This target implies a projected price-to-earnings ratio of 9.3 times for the current year.

The report noted that the company's revenue last year increased by 4.6% year-over-year to RMB 269.56 billion, while attributable net profit rose by 20.7% to RMB 4.05 billion. Management indicated that excluding one-time items such as impairment losses, net profit grew by 14% compared to the prior year. UBS highlighted that the annual revenue was in line with market expectations, while profit exceeded forecasts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment